News
TEVA
34.37
-0.29%
-0.10
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes
Simply Wall St · 1d ago
Teva Pharmaceuticals Price Target Raised to $45.00/Share From $36.00 by Goldman Sachs
Dow Jones · 1d ago
Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $45
Benzinga · 1d ago
Goldman Sachs Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
TipRanks · 1d ago
Teva price target raised to $45 from $36 at Goldman Sachs
TipRanks · 1d ago
HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES RAISES PASSIVE STAKE IN TEVA TO 6.3% AS OF DEC 31, 2025 FROM 5.1% AS OF SEPT 29, 2025 - FILING
Reuters · 2d ago
Weekly Report: what happened at TEVA last week (0202-0206)?
Weekly Report · 2d ago
Teva (TEVA) Q4 2024 Earnings Call Transcript
The Motley Fool · 5d ago
Teva (TEVA) Q3 2024 Earnings Call Transcript
The Motley Fool · 5d ago
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings
Benzinga · 5d ago
Harel Insurance Sold $330 Million of Invesco KBW Bank ETF
The Motley Fool · 5d ago
Teva Pharma's Subsidiary Teva Canada Says Health Canada Approves Expanded Indication For PrAJOVY For Prevention Of Episodic Migraine In Pediatric Patients Aged 6 To 17 Years And Weighing At Least 45 Kg
Benzinga · 6d ago
Health Canada Approves Teva's AJOVY for Pediatric Episodic Migraine Prevention
Reuters · 6d ago
Health Canada genehmigt PrAJOVY von Teva für Migräneprävention bei Kindern und Jugendlichen
Reuters · 6d ago
TEVA CANADA ANNOUNCES APPROVAL OF EXPANDED INDICATION OF [PR]AJOVY® (FREMANEZUMAB SOLUTION FOR SUBCUTANEOUS INJECTION), THE FIRST ANTI-CGRP PREVENTIVE TREATMENT FOR PEDIATRIC EPISODIC MIGRAINE
Reuters · 6d ago
Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands
TipRanks · 02/04 06:00
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate
Simply Wall St · 02/03 22:27
Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA
NASDAQ · 02/03 15:57
Teva posts FY non-GAAP net income of USD 3.41 billion, up 19%
Reuters · 02/03 14:00
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.